Abstract

IntroductionTissue plasminogen activator (tPA)-activity and plasminogen activator inhibitor type 1 (PAI-1) antigen are considered to be haemostasis-related markers of endothelial activation and relate to presence of cerebral white matter hyperintensities (WMH) as was earlier shown in a cross-sectional study. We investigated whether tPA-activity and PAI-1 levels are associated with WMH progression in a longitudinal study.MethodsIn 127 first-ever lacunar stroke patients in whom baseline brain MRI and plasma levels of tPA-activity and PAI-1-antigen were available, we obtained a 2-year follow-up MRI. We assessed WMH progression by a visual WMH change scale. We determined the relationship between levels of tPA-activity and PAI-1 and WMH progression, by logistic regression analysis.ResultsPlasma tPA-activity was associated with periventricular WMH progression (OR 2.36, 95% CI 1.01–5.49, with correction for age and sex and baseline presence of WMH), but not with deep or any (periventricular and/or deep) WMH progression. PAI-1 levels were lower in patients with WMH progression, but these results were not significant.ConclusionWe found a relationship between plasma tPA-activity and progression of periventricular WMH. More research is needed to determine whether there is a (direct) role of tPA in the development and progression of WMH.

Highlights

  • OPEN ACCESSCitation: van Overbeek EC, Staals J, Knottnerus ILH, ten Cate H, van Oostenbrugge RJ (2016) Plasma Tissue plasminogen activator (tPA)-Activity and Progression of Cerebral White Matter Hyperintensities in Lacunar Stroke Patients

  • We investigated whether tPA-activity and plasminogen activator inhibitor type 1 (PAI-1) levels are associated with white matter hyperintensities (WMH) progression in a longitudinal study

  • Plasma tPA-activity was associated with periventricular WMH progression, but not with deep or any WMH progression

Read more

Summary

Introduction

We investigated whether tPA-activity and PAI-1 levels are associated with WMH progression in a longitudinal study

Objectives
Methods
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.